figitumumab
mAbexperimental
Figitumumab is a monoclonal antibody targeting the insulin-like growth factor-1 receptor that was investigated for the treatment of various types of cancer, for example adrenocortical carcinoma and non-small cell lung cancer (NSCLC). — Wikipedia
Clinical trial activity
21 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
12
Phase 2
11
Phase 3
3
Phase 4
0
Earliest trial started Dec 1, 2003 (NCT01536145)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 2
- Carcinoma, Adenosquamous · Phase 3
- Carcinoma, Large Cell · Phase 3
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Squamous Cell · Phase 3
- Colorectal Neoplasms · Phase 2
- Head and Neck Neoplasms · Phase 2
- Healthy Volunteers · Phase 1
- Lung Neoplasms · Phase 1
- Multiple Myeloma · Phase 1
- Neoplasms · Phase 1
- Prostatic Neoplasms · Phase 2
- Sarcoma · Phase 1
- Sarcoma, Ewing · Phase 1/Phase 2
- Small Cell Lung Carcinoma · Phase 2
Mechanism of action
- Insulin-like growth factor I receptorANTAGONIST
IGF1R antagonist
Blocks binding of IGF-1 to its receptor (IGF1R) and specifically inhibits the IGF-1-induced receptor autophosphorylation.
IGF1R inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFigitumumab ↗
- ChEMBLCHEMBL1743019 ↗
Also known as
- 871
- 871
- cp-751
- cp-751
- cp751871
- cp 751871
- cp 751,871
- cp 751,871
- cp 751,871
- cp-751871
- cp-751871
- cp-751871
- cp-751,871
- cp-751,871
- cp-751,871
- cp751,871
- figitumumab
- figitumumab
- figitumumab
- figitumumab
- figitumumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00907504 | Phase 3 | Jul 1, 2010 | Pfizer |
| NCT00977561 | Phase 2 | Apr 1, 2010 | Pfizer |
| NCT00976508 | Phase 1 | Nov 1, 2009 | Pfizer |
| NCT00927966 | Phase 1 | Jul 1, 2009 | Harvard University, Novartis, Pfizer |
| NCT00926263 | Phase 1 | Jul 1, 2009 | Pfizer |
| NCT00678626 | Phase 2 | Apr 1, 2009 | Pfizer |
| NCT00872404 | Phase 2 | Jan 1, 2009 | Université catholique de Louvain |
| NCT00729833 | Phase 1 | Sep 1, 2008 | Pfizer |
| NCT00673049 | Phase 3 | May 1, 2008 | Pfizer |
| NCT00596830 | Phase 3 | Apr 1, 2008 | Pfizer |
| NCT00635245 | Phase 1 | Mar 12, 2008 | National Cancer Institute (NCI), Pfizer, University of Minnesota |
| NCT00560235 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2008 | Pfizer |
| NCT00603538 | Phase 1 | Jan 1, 2008 | Pfizer |
| NCT00560560 | Phase 2 | Dec 1, 2007 | Pfizer |
| NCT00560573 | Phase 1 | Nov 1, 2007 | Pfizer |
| NCT00372996 | Phase 2 | Feb 1, 2007 | Pfizer |
| NCT00313781 | Phase 2 | May 1, 2006 | Pfizer |
| NCT00474760 | Phase 1 | Aug 1, 2005 | Pfizer |
| NCT01653158 | Phase 1 | Mar 1, 2005 | Pfizer |
| NCT00147537 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2005 | Pfizer |
Showing 20 of 21 trials
Page 1 / 2
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 20 | 19 | 3 | 2003 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2009 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2008 |
| Novartis | For profit | 1 | 0 | 1 | 2009 |
| Université catholique de Louvain | Academic/Hospital | 1 | 1 | 1 | 2009 |
| University of Minnesota | Academic/Hospital | 1 | 0 | 1 | 2008 |
6 organizations
Page 1 / 1